#1 Clinical Trials Search in Europe

Lib-01 Monohydrate

LIB-01 Monohydrate is an investigational drug currently being studied for the treatment of erectile dysfunction (ED) in adult men. This article explores the ongoing clinical trials, their objectives, and potential benefits of this new medication in addressing a common men’s health issue.

Table of Contents

What is LIB-01 MONOHYDRATE?

LIB-01 MONOHYDRATE is a new medication being developed to treat erectile dysfunction (ED) in adult men[1]. Erectile dysfunction is a condition where a man has difficulty getting or maintaining an erection firm enough for sexual intercourse. This new drug is currently being tested to see if it can help improve sexual function for men with ED.

How Does LIB-01 Work?

While the exact mechanism of action is not fully described in the available information, LIB-01 MONOHYDRATE is being developed as an oral medication to treat erectile dysfunction[1]. It comes in the form of a powder that is mixed into a liquid suspension before taking it by mouth. The drug is designed to help improve a man’s ability to get and maintain an erection during sexual activity.

Current Clinical Trial

LIB-01 MONOHYDRATE is currently being studied in a Phase 2a clinical trial[1]. This is an important step in testing new medications to determine if they are safe and effective. The trial is described as:

  • Randomized: Participants are randomly assigned to different treatment groups
  • Double-blind: Neither the participants nor the researchers know who is receiving which treatment
  • Placebo-controlled: Some participants receive an inactive substance (placebo) to compare with the actual medication

The main goal of this trial is to evaluate how well LIB-01 works for treating erectile dysfunction and to assess its safety[1].

Dosage and Administration

In this clinical trial, researchers are testing three different dose levels of LIB-01 MONOHYDRATE[1]:

  1. 10 mg once daily for 3 days
  2. 25 mg once daily for 3 days
  3. 50 mg once daily for 3 days

The medication is given as an oral suspension, which means the powder is mixed with a liquid before taking it by mouth. Some participants will receive a placebo instead of the active medication for comparison.

Who Can Participate in the Trial?

The trial is looking for men who meet specific criteria[1], including:

  • Age 25 to 65 years old
  • In a stable heterosexual relationship for at least 6 months
  • Diagnosed with erectile dysfunction based on a questionnaire score
  • Highly motivated to seek treatment for ED

There are also several conditions that would exclude someone from participating, such as certain medical histories or medications that might interfere with the study.

Safety Considerations

As with any new medication, safety is a top priority. The researchers will be closely monitoring participants for any side effects or adverse events[1]. They will be checking:

  • Vital signs
  • Blood tests
  • Electrocardiograms (ECGs) to monitor heart activity

Participants will have several follow-up visits to ensure their safety throughout the trial period.

Measuring Effectiveness

To determine how well LIB-01 MONOHYDRATE works, the researchers will use several methods[1]:

  • Questionnaires about erectile function and sexual satisfaction
  • Tracking successful sexual encounters
  • Asking participants if they noticed improvements in their erections

The researchers will compare the results from men taking LIB-01 to those taking the placebo to see if the medication makes a significant difference.

In conclusion, LIB-01 MONOHYDRATE represents a potential new treatment option for men with erectile dysfunction. While it’s still in the testing phase, this clinical trial will provide important information about its safety and effectiveness. If successful, it could offer another choice for men seeking help with ED in the future.

Aspect Details
Drug Name LIB-01 Monohydrate
Condition Studied Erectile Dysfunction (ED)
Trial Phase Phase 2a
Trial Design Randomized, Double-blind, Parallel, Placebo-controlled
Dosage Forms Oral suspension: 10 mg, 25 mg, 50 mg
Treatment Duration 3 days
Primary Objectives Evaluate efficacy and safety of LIB-01 in treating ED
Key Assessments IIEF-EF score, SEP, GAQ, Safety parameters
Participant Age Range 25 to 65 years
Total Trial Duration Approximately 8 weeks

FAQ

  • What is LIB-01 Monohydrate? LIB-01 Monohydrate is an investigational drug being studied as a potential treatment for erectile dysfunction in adult men. It is administered as an oral suspension.
  • How is the clinical trial for LIB-01 Monohydrate designed? The trial is a Phase 2a, randomized, double-blind, parallel, and placebo-controlled study. Participants are randomly assigned to receive either LIB-01 at doses of 10 mg, 25 mg, 50 mg, or a placebo, taken once daily for 3 days.
  • What are the main objectives of the LIB-01 Monohydrate clinical trial? The primary objectives are to evaluate the efficacy of LIB-01 in treating erectile dysfunction and to assess its safety. Secondary objectives include improving various aspects of erectile function and studying the drug's pharmacokinetics.
  • Who can participate in the LIB-01 Monohydrate clinical trial? The trial is open to men aged 25 to 65 years who have been in a stable heterosexual relationship for at least 6 months, have erectile dysfunction, and meet specific criteria regarding their erectile function score. There are also several exclusion criteria to ensure participant safety.
  • How long does the LIB-01 Monohydrate clinical trial last? The trial lasts approximately 8 weeks, with multiple follow-up visits after the initial 3-day dosing period. The final visit occurs on Day 56, or earlier if a participant withdraws from the study.

Ongoing Clinical Trials on Lib-01 Monohydrate

  • Study on the Safety and Effectiveness of LIB-01 for Treating Erectile Dysfunction in Adult Men

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Denmark The Netherlands Sweden

Glossary

  • Erectile Dysfunction (ED): A condition where a man has difficulty achieving or maintaining an erection sufficient for satisfactory sexual performance.
  • Phase 2a Trial: An early stage of clinical research that aims to assess the effectiveness and safety of a new drug in a small group of patients with the target condition.
  • Randomized: A method of assigning participants to different treatment groups by chance, to reduce bias in the study results.
  • Double-blind: A study design where neither the participants nor the researchers know who is receiving the actual treatment or placebo, to prevent bias.
  • Placebo: An inactive substance that looks like the drug being tested but has no medical effect, used to compare results with the actual treatment.
  • Efficacy: The ability of a treatment to produce the desired beneficial effect under ideal circumstances.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • International Index of Erectile Function (IIEF): A standardized questionnaire used to assess erectile function and other aspects of sexual health in men.
  • Sexual Encounter Profile (SEP): A set of questions used to evaluate the success of sexual encounters in clinical trials for erectile dysfunction treatments.
  • Global Assessment Question (GAQ): A question used to assess overall improvement in erections during a clinical trial for erectile dysfunction treatments.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-lib-01-for-treating-erectile-dysfunction-in-adult-men/